Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli

Hanna E. Sidjabat, David L. Paterson, Zubair A. Qureshi, Jennifer M. Adams-Haduch, Alexandra O'Keefe, Alvaro Pascual, Jesús Rodríguez-Bão, Yohei Doi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background. Knowledge of the clinical features of infections caused by Escherichia coli strains that produce plasmid-mediated AmpC β-lactamase is limited. Of the several groups of plasmid-mediated AmpC β-lactamases, CMY-type β-lactamase is the most common in the United States. Methods. We prospectively identified patients infected or colonized with E. coli strains that produce CMY-type β-lactamase, and we collected clinical data over a 7-month period. A retrospective cohort study was performed to identify features associated with these cases. Patients with extended-spectrum β-lactamase-producing E. coli were used as a control group. Pulsed-field gel electrophoresis, plasmid analysis, and phylogenetic typing were performed. Results. Twenty-two patients with infection or colonization due to CMY-type β-lactamase-producing E. coli and 25 patients with infection or colonization due to extended-spectrum β-lactamase-producing E. coli were identified. The demographic characteristics of the patients were similar in both cohorts. Patients with CMY-type β-lactamase-producing E. coli were significantly more likely to have symptomatic infection than were patients with extended-spectrum β-lactamase-producing E. coli (P = .028). The CMY-type β-lactamase was identified as CMY-2 or its variants. Ninety-four percent of the CMY-type β-lactamase-producing isolates belonged to E. coli phylogenetic groups B2 and D, which are associated with virulence. Many of the isolates shared similar plasmid profiles, whereas the pulsed-field gel electrophoresis profiles were diverse. Co-resistance to non-β-lactam antimicrobials was common. Conclusion. In Pittsburgh, Pennsylvania, CMY-type β-lactamase-producing E. coli strains are almost as common as extended-spectrum β-lactamase-producing E. coli strains, and they cause symptomatic infection in the majority of cases.

Original languageEnglish
Pages (from-to)739-744
Number of pages6
JournalClinical Infectious Diseases
Volume48
Issue number6
DOIs
Publication statusPublished - 15-03-2009
Externally publishedYes

Fingerprint

Molecular Epidemiology
Escherichia coli
Plasmids
Pulsed Field Gel Electrophoresis
Infection
Escherichia coli Infections
Lactams
Virulence
Cohort Studies
Retrospective Studies
Demography
Control Groups

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Sidjabat, H. E., Paterson, D. L., Qureshi, Z. A., Adams-Haduch, J. M., O'Keefe, A., Pascual, A., ... Doi, Y. (2009). Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli. Clinical Infectious Diseases, 48(6), 739-744. https://doi.org/10.1086/597037
Sidjabat, Hanna E. ; Paterson, David L. ; Qureshi, Zubair A. ; Adams-Haduch, Jennifer M. ; O'Keefe, Alexandra ; Pascual, Alvaro ; Rodríguez-Bão, Jesús ; Doi, Yohei. / Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli. In: Clinical Infectious Diseases. 2009 ; Vol. 48, No. 6. pp. 739-744.
@article{d8a1a26ca6cd4a07985edc2423c168cd,
title = "Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli",
abstract = "Background. Knowledge of the clinical features of infections caused by Escherichia coli strains that produce plasmid-mediated AmpC β-lactamase is limited. Of the several groups of plasmid-mediated AmpC β-lactamases, CMY-type β-lactamase is the most common in the United States. Methods. We prospectively identified patients infected or colonized with E. coli strains that produce CMY-type β-lactamase, and we collected clinical data over a 7-month period. A retrospective cohort study was performed to identify features associated with these cases. Patients with extended-spectrum β-lactamase-producing E. coli were used as a control group. Pulsed-field gel electrophoresis, plasmid analysis, and phylogenetic typing were performed. Results. Twenty-two patients with infection or colonization due to CMY-type β-lactamase-producing E. coli and 25 patients with infection or colonization due to extended-spectrum β-lactamase-producing E. coli were identified. The demographic characteristics of the patients were similar in both cohorts. Patients with CMY-type β-lactamase-producing E. coli were significantly more likely to have symptomatic infection than were patients with extended-spectrum β-lactamase-producing E. coli (P = .028). The CMY-type β-lactamase was identified as CMY-2 or its variants. Ninety-four percent of the CMY-type β-lactamase-producing isolates belonged to E. coli phylogenetic groups B2 and D, which are associated with virulence. Many of the isolates shared similar plasmid profiles, whereas the pulsed-field gel electrophoresis profiles were diverse. Co-resistance to non-β-lactam antimicrobials was common. Conclusion. In Pittsburgh, Pennsylvania, CMY-type β-lactamase-producing E. coli strains are almost as common as extended-spectrum β-lactamase-producing E. coli strains, and they cause symptomatic infection in the majority of cases.",
author = "Sidjabat, {Hanna E.} and Paterson, {David L.} and Qureshi, {Zubair A.} and Adams-Haduch, {Jennifer M.} and Alexandra O'Keefe and Alvaro Pascual and Jes{\'u}s Rodr{\'i}guez-B{\~a}o and Yohei Doi",
year = "2009",
month = "3",
day = "15",
doi = "10.1086/597037",
language = "English",
volume = "48",
pages = "739--744",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

Sidjabat, HE, Paterson, DL, Qureshi, ZA, Adams-Haduch, JM, O'Keefe, A, Pascual, A, Rodríguez-Bão, J & Doi, Y 2009, 'Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli', Clinical Infectious Diseases, vol. 48, no. 6, pp. 739-744. https://doi.org/10.1086/597037

Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli. / Sidjabat, Hanna E.; Paterson, David L.; Qureshi, Zubair A.; Adams-Haduch, Jennifer M.; O'Keefe, Alexandra; Pascual, Alvaro; Rodríguez-Bão, Jesús; Doi, Yohei.

In: Clinical Infectious Diseases, Vol. 48, No. 6, 15.03.2009, p. 739-744.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli

AU - Sidjabat, Hanna E.

AU - Paterson, David L.

AU - Qureshi, Zubair A.

AU - Adams-Haduch, Jennifer M.

AU - O'Keefe, Alexandra

AU - Pascual, Alvaro

AU - Rodríguez-Bão, Jesús

AU - Doi, Yohei

PY - 2009/3/15

Y1 - 2009/3/15

N2 - Background. Knowledge of the clinical features of infections caused by Escherichia coli strains that produce plasmid-mediated AmpC β-lactamase is limited. Of the several groups of plasmid-mediated AmpC β-lactamases, CMY-type β-lactamase is the most common in the United States. Methods. We prospectively identified patients infected or colonized with E. coli strains that produce CMY-type β-lactamase, and we collected clinical data over a 7-month period. A retrospective cohort study was performed to identify features associated with these cases. Patients with extended-spectrum β-lactamase-producing E. coli were used as a control group. Pulsed-field gel electrophoresis, plasmid analysis, and phylogenetic typing were performed. Results. Twenty-two patients with infection or colonization due to CMY-type β-lactamase-producing E. coli and 25 patients with infection or colonization due to extended-spectrum β-lactamase-producing E. coli were identified. The demographic characteristics of the patients were similar in both cohorts. Patients with CMY-type β-lactamase-producing E. coli were significantly more likely to have symptomatic infection than were patients with extended-spectrum β-lactamase-producing E. coli (P = .028). The CMY-type β-lactamase was identified as CMY-2 or its variants. Ninety-four percent of the CMY-type β-lactamase-producing isolates belonged to E. coli phylogenetic groups B2 and D, which are associated with virulence. Many of the isolates shared similar plasmid profiles, whereas the pulsed-field gel electrophoresis profiles were diverse. Co-resistance to non-β-lactam antimicrobials was common. Conclusion. In Pittsburgh, Pennsylvania, CMY-type β-lactamase-producing E. coli strains are almost as common as extended-spectrum β-lactamase-producing E. coli strains, and they cause symptomatic infection in the majority of cases.

AB - Background. Knowledge of the clinical features of infections caused by Escherichia coli strains that produce plasmid-mediated AmpC β-lactamase is limited. Of the several groups of plasmid-mediated AmpC β-lactamases, CMY-type β-lactamase is the most common in the United States. Methods. We prospectively identified patients infected or colonized with E. coli strains that produce CMY-type β-lactamase, and we collected clinical data over a 7-month period. A retrospective cohort study was performed to identify features associated with these cases. Patients with extended-spectrum β-lactamase-producing E. coli were used as a control group. Pulsed-field gel electrophoresis, plasmid analysis, and phylogenetic typing were performed. Results. Twenty-two patients with infection or colonization due to CMY-type β-lactamase-producing E. coli and 25 patients with infection or colonization due to extended-spectrum β-lactamase-producing E. coli were identified. The demographic characteristics of the patients were similar in both cohorts. Patients with CMY-type β-lactamase-producing E. coli were significantly more likely to have symptomatic infection than were patients with extended-spectrum β-lactamase-producing E. coli (P = .028). The CMY-type β-lactamase was identified as CMY-2 or its variants. Ninety-four percent of the CMY-type β-lactamase-producing isolates belonged to E. coli phylogenetic groups B2 and D, which are associated with virulence. Many of the isolates shared similar plasmid profiles, whereas the pulsed-field gel electrophoresis profiles were diverse. Co-resistance to non-β-lactam antimicrobials was common. Conclusion. In Pittsburgh, Pennsylvania, CMY-type β-lactamase-producing E. coli strains are almost as common as extended-spectrum β-lactamase-producing E. coli strains, and they cause symptomatic infection in the majority of cases.

UR - http://www.scopus.com/inward/record.url?scp=62449219508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449219508&partnerID=8YFLogxK

U2 - 10.1086/597037

DO - 10.1086/597037

M3 - Article

C2 - 19187027

AN - SCOPUS:62449219508

VL - 48

SP - 739

EP - 744

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -

Sidjabat HE, Paterson DL, Qureshi ZA, Adams-Haduch JM, O'Keefe A, Pascual A et al. Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli. Clinical Infectious Diseases. 2009 Mar 15;48(6):739-744. https://doi.org/10.1086/597037